{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:40:26Z","timestamp":1774525226398,"version":"3.50.1"},"reference-count":85,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VtR Inc-CGU, R.O.C.","award":["SCRPD1L0221"],"award-info":[{"award-number":["SCRPD1L0221"]}]},{"name":"VtR Inc-CGU, R.O.C.","award":["SCRPD1K0131"],"award-info":[{"award-number":["SCRPD1K0131"]}]},{"name":"VtR Inc-CGU, R.O.C.","award":["UZRPD1L0011"],"award-info":[{"award-number":["UZRPD1L0011"]}]},{"name":"DOXABIO-CGU, R.O.C.","award":["SCRPD1L0221"],"award-info":[{"award-number":["SCRPD1L0221"]}]},{"name":"DOXABIO-CGU, R.O.C.","award":["SCRPD1K0131"],"award-info":[{"award-number":["SCRPD1K0131"]}]},{"name":"DOXABIO-CGU, R.O.C.","award":["UZRPD1L0011"],"award-info":[{"award-number":["UZRPD1L0011"]}]},{"name":"CGU","award":["SCRPD1L0221"],"award-info":[{"award-number":["SCRPD1L0221"]}]},{"name":"CGU","award":["SCRPD1K0131"],"award-info":[{"award-number":["SCRPD1K0131"]}]},{"name":"CGU","award":["UZRPD1L0011"],"award-info":[{"award-number":["UZRPD1L0011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>With the ongoing COVID-19 pandemic, the emergence of the novel Omicron variant in November 2021 has created chaos around the world. Despite mass vaccination, Omicron has spread rapidly, raising concerns around the globe. The Omicron variant has a vast array of mutations, as compared to another variant of concern, with a total of 50 mutations, 30 of which are present on its spike protein alone. These mutations have led to immune escape and more transmissibility compared to other variants, including the Delta variant. A cluster of mutations (H655Y, N679K, and P681H) present in the Omicron spike protein could aid in transmission. Currently, no virus-specific data are available to predict the efficacy of the anti-viral and mAbs drugs. However, two monoclonal antibody drugs, Sotrovimab and Evusheld, are authorized for emergency use in COVID-19 patients. This virus is not fading away soon. The easiest solution and least expensive measure to fight against this pandemic are to follow the appropriate COVID-19 protocols. There is a need to strengthen the level of research for the development of potential vaccines and anti-viral drugs. It is also important to monitor and expand the genomic surveillance to keep track of the emergence of new variants, thus avoiding the spread of new diseases worldwide. This article highlights the emergence of the new SARS-CoV-2 variant of concern, Omicron (B.1.1.529), and the vast number of mutations in its protein. In addition, recent advancements in drugs approved by FDA to treat COVID patients have been listed and focused in this paper.<\/jats:p>","DOI":"10.3390\/vaccines10091468","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T20:50:27Z","timestamp":1662670227000},"page":"1468","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-5086","authenticated-orcid":false,"given":"Beyau M.","family":"Konyak","sequence":"first","affiliation":[{"name":"Integrated Molecular Diagnostic and Research Laboratory (BSL-2), District Hospital Tuensang, Tuensang 798612, Nagaland, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9607-0630","authenticated-orcid":false,"given":"Mohan","family":"Sharma","sequence":"additional","affiliation":[{"name":"Integrated Molecular Diagnostic and Research Laboratory (BSL-2), District Hospital Tuensang, Tuensang 798612, Nagaland, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Kharia","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Dibrugarh University, Dibrugarh 786004, Assam, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-6468","authenticated-orcid":false,"given":"Ramendra Pati","family":"Pandey","sequence":"additional","affiliation":[{"name":"Centre for Drug Design Discovery and Development (C4D), Department of Biotechnology & Microbiology SRM University, Delhi-NCR, Rajiv Gandhi Education City, Sonepat 131029, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Ming","family":"Chang","sequence":"additional","affiliation":[{"name":"Master & Ph.D. Program in Biotechnology Industry, Division of Biotechnology, Chang Gung University, No. 259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2022, February 14). WHO Coronavirus (COVID-19) Dashboard with Vaccination Data, Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/jmv.27563","article-title":"Omicron (B.1.1.529) variant: Development, dissemination, and dominance","volume":"94","author":"Rahmani","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_3","unstructured":"(2022, February 20). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_4","unstructured":"World Health Organization (WHO) (2022, January 05). Classification of Omicron (B.1.1.529): SARSCoV-2 Variant of Concern, Available online: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"UNICEF (2022, February 16). What We Know about the Omicron Variant. Available online: https:\/\/www.unicef.org\/coronavirus\/what-we-know-about-omicron-variant.","DOI":"10.5812\/archcid.122784"},{"key":"ref_6","unstructured":"CDC (2022, February 16). Science Brief: Omicron (B.1.1.529) Variant (Updated 2 December 2021), Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/scientific-brief-omicron-variant.html."},{"key":"ref_7","unstructured":"UK Health Security Agency (2022, February 14). SARS-CoV-2 Variants of Concern and Variants under Investigation, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1036501\/Technical_Briefing_29_published_26_November_2021.pdf."},{"key":"ref_8","unstructured":"Harvard Medical School (2022, January 11). Coronavirus Resource Center\u2014Harvard Health. Harvard Health Publishing. Lab Studies, Animal Studies, and Epidemiological Data All Indicate That Omicron May Cause Less Severe Disease Than Previous Variants. Available online: https:\/\/www.health.harvard.edu\/diseases-and-conditions\/coronavirus-resource-center."},{"key":"ref_9","unstructured":"Leonhardt, D. (2022, January 07). Omicron Is Milder, The New York Times, Available online: https:\/\/www.nytimes.com\/2022\/01\/05\/briefing\/omicron-risk-milder-pandemic.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","article-title":"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)\u2014Highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts","volume":"114","author":"Petersen","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/jmv.27561","article-title":"Omicron (B.1.1.529 variant of SARS-CoV-2); An emerging threat: Current global scenario","volume":"94","author":"Mohapatra","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_12","unstructured":"WHO (2021, November 28). Less than 10% of African Countries to Hit Key COVID-19 Vaccination Goal, Available online: https:\/\/www.afro.who.int\/news\/less-10-african-countries-hit-key-covid-19-vaccination-goal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1093\/cid\/ciab1072","article-title":"Two cases of breakthrough SARS-CoV-2 infections caused by the Omicron variant (B.1.1.529 lineage) in international travelers to Japan","volume":"75","author":"Maruki","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","unstructured":"(2022, January 06). First Omicron Cases Detected in India. Available online: https:\/\/thehill.com\/policy\/international\/583965-first-omicron-cases-detected-in-india."},{"key":"ref_15","unstructured":"(2022, January 06). Germany Reports First Two Cases of Omicron Variant. Available online: https:\/\/www.thejournal.ie\/germany-omicron-coronavirus-covid-19-bavaria-5613843-Nov2021\/."},{"key":"ref_16","unstructured":"GISAID (2021, November 30). Tracking of Variants. Available online: https:\/\/www.gisaid.org\/hcov19-variants\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.15585\/mmwr.mm705152e3","article-title":"Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster\u2014Nebraska, november-december 2021","volume":"70","author":"Jansen","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_18","unstructured":"National Institute of Infectious Diseases, Japan (2022, January 22). Active Epidemiological Investigation on SARS-CoV-2 Infection Caused by Omicron Variant (Pango Lineage B.1.1.529 in Japan: Preliminary Report on Infectious Period, Available online: https:\/\/www.niid.go.jp\/niid\/en\/2019-ncov-e\/10884-covid19-66-en.html."},{"key":"ref_19","unstructured":"UK Health Security Agency (2022, February 06). SARS-CoV-2 Variants of Concern and Variants under Investigation in England, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1050999\/Technical-Briefing-35-28January2022.pdf."},{"key":"ref_20","unstructured":"Washington Post (2022, January 25). There\u2019s a New Version of Omicron but So Far It Doesn\u2019t Appear to Be More Dangerous. Available online: https:\/\/www.stripes.com\/covid\/2022-01-25\/new-omicron-version-mutation-BA-2-4405690.html."},{"key":"ref_21","unstructured":"(2022, February 11). Outbreak.Info. BA.2 Lineage Report. Available online: https:\/\/outbreak.info\/situation-reports?pango=BA.2."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lyngse, F.P., Kirkeby, C., Denwood, M., Christiansen, L.E., M\u00f8lbak, K., M\u00f8ller, C.H., Skov, R., Krause, T., Rasmussen, M., and Sieber, R. (2022). Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv.","DOI":"10.1101\/2022.01.28.22270044"},{"key":"ref_23","unstructured":"(2022, February 07). Omicron BA.2: What We Know about the Covid Sub-Variant. Available online: https:\/\/www.bbc.com\/news\/health-60233899."},{"key":"ref_24","unstructured":"GISAID (2022, February 10). hCoV-19 Tracking of Variants. Available online: https:\/\/www.epicov.org\/epi3\/frontend#58aca."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.acx9782","article-title":"How bad is Omicron? Some clues are emerging","volume":"374","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"ref_26","first-page":"5857","article-title":"Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies","volume":"25","author":"Wahid","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbrc.2021.12.079","article-title":"Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor","volume":"590","author":"Lupala","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","first-page":"3","article-title":"The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism","volume":"23","author":"Willett","year":"2022","journal-title":"medRxiv"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jmv.27524","article-title":"Characterization of the novel SARS-CoV-2 omicron (B.1.1.529) variant of concern and its global perspective","volume":"94","author":"Saxena","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-021-00863-2","article-title":"SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"ref_33","unstructured":"Corum, J., and Zimmer, C. (2022, January 07). Tracking Omicron and Other Coronavirus Variants. Available online: https:\/\/www.nytimes.com\/interactive\/2021\/health\/coronavirus-variant-tracker.html."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.tmaid.2021.102234","article-title":"Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts\u2014What is known so far?","volume":"45","author":"Poudel","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_35","unstructured":"Science the Wire (2022, January 07). A \u2018Stealth\u2019 Version of Omicron Could Challenge Surveillance Efforts. Available online: https:\/\/science.thewire.in\/external-affairs\/world\/ba-2-sublineage-omicron-s-gene-target-failure-surveillance\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102242","DOI":"10.1016\/j.tmaid.2021.102242","article-title":"Omicron N501Y mutation among SARS-CoV-2 lineages: Insilico analysis of potent binding to tyrosine kinase and hypothetical repurposed medicine","volume":"45","author":"Kazybay","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11357-021-00500-4","article-title":"Omicron variant of the SARS-CoV-2: A quest to define the consequences of its high mutational load","volume":"44","author":"Quarleri","year":"2022","journal-title":"Geroscience"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41598-022-04950-4","article-title":"Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis","volume":"12","author":"Negi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.20411\/pai.v6i2.460","article-title":"Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K\/G204R variant in nucleocapsid: Homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level","volume":"6","author":"Leary","year":"2021","journal-title":"Pathog. Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41467-022-28287-8","article-title":"SARS-CoV-2 genomes from Saudi Arabia implicate nucleocapsid mutations in host response and increased viral load","volume":"13","author":"Mourier","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102779","DOI":"10.1016\/j.jaut.2021.102779","article-title":"Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies","volume":"126","author":"Kannan","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"ref_46","unstructured":"World Health Organization (2021, June 22). Tracking SARS-CoV-2 Variants, Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2020-DON305."},{"key":"ref_47","unstructured":"Therapeutic Goods Administration (TGA) (2021, December 15). COVID-19 Rapid Antigen Self-Tests That Are Approved in Australia, Available online: https:\/\/www.tga.gov.au\/covid-19-rapid-antigen-self-tests-are-approved-australia."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104846","DOI":"10.1016\/j.jcv.2021.104846","article-title":"SARS-CoV-2 rapid antigen test: High sensitivity to detect infectious virus","volume":"140","author":"Nordgren","year":"2021","journal-title":"J. Clin. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0247921","DOI":"10.1128\/jcm.02479-21","article-title":"Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV-2 Omicron Variant","volume":"60","author":"Deerain","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bekliz, M., Perez-Rodriguez, F., Puhach, O., Adea, K., Melancia, S.M., Baggio, S., Corvaglia, A., Jacquerioz-Bausch, F., Alvarez, C., and Essaidi-Laziosi, M. (2021). Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. medRxiv.","DOI":"10.1101\/2021.12.18.21268018"},{"key":"ref_51","unstructured":"U.S. Food & Drug Administration (2022, January 06). SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests, Available online: https:\/\/www.fda.gov\/medical-devices\/coronavirus-covid-19-and-medical-devices\/sars-cov-2-viral-mutations-impact-covid-19-tests.ccessed."},{"key":"ref_52","unstructured":"(2022, January 06). Comparative Evaluation of the Sensitivity of SARS-CoV-2 Rapid Antigen Tests (Self-Tests + Rapid Tests). Available online: https:\/\/www.pei.de\/DE\/newsroom\/dossier\/coronavirus\/testsysteme.html."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Adamson, B., Sikka, R., Wyllie, A.L., and Premsrirut, P. (2021). Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series. medRxiv.","DOI":"10.1101\/2022.01.04.22268770"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schrom, J., Marquez, C., Pilarowski, G., Wang, G., Mitchell, A., Puccinelli, R., Black, D., Rojas, S., Ribeiro, S., and Martinez, J. (2022). Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOW\u2122) at a Community Testing Site During an Omicron Surge. medRxiv, 22268954.","DOI":"10.1101\/2022.01.08.22268954"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3201\/eid2711.211449","article-title":"Effectiveness of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in Outbreak among Horse Racetrack Workers, California, USA","volume":"27","author":"Surasi","year":"2021","journal-title":"Emerg. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1515\/cclm-2021-1287","article-title":"Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: Urgent call for validation against new and highly mutated variants","volume":"60","author":"Lippi","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"w30120","DOI":"10.4414\/SMW.2021.w30120","article-title":"PCR performance in the SARS-CoV-2 Omicron variant of concern?","volume":"151","author":"Metzger","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"114462","DOI":"10.1016\/j.jviromet.2022.114462","article-title":"SARS-CoV-2 multiplex RT-PCR to detect variants of concern (VOCs) in Malaysia, between January to May 2021","volume":"301","author":"Fu","year":"2022","journal-title":"J. Virol. Methods"},{"key":"ref_59","unstructured":"Centers for Disease Control and Prevention (CDC) (2022, January 05). Science Brief: Emerging SARSCoV-2 Variants, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/science\/science-briefs\/scientific-brief-emerging-variants.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F201,%209-ncov%2Fmore%2Fscience-and-research%2Fscientific-brief-emerging-variants.html."},{"key":"ref_60","unstructured":"(2022, February 20). IGM Biosciences Advances Novel Antibody IGM-6268 into Clinical Trials for the Treatment and Prevention of COVID-19. Available online: https:\/\/www.biospace.com\/article\/releases\/igm-biosciences-advances-novel-antibody-igm-6268-into-clinical-trials-for-the-treatment-and-prevention-of-covid-19-\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8903435","DOI":"10.1155\/2021\/8903435","article-title":"Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review","volume":"2021","author":"Chamlagain","year":"2021","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"ref_62","unstructured":"CORIMUNO-19 Collaborative Group (2022). Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatol., 4, E24\u2013E32."},{"key":"ref_63","unstructured":"(2022, February 19). WHO Approves 2 New COVID-19 Treatments Amid Omicron. Available online: https:\/\/www.thevibes.com\/articles\/world\/52032\/who-approves-2-new-covid-19-treatments-amid-omicron."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"RECOVERY Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., and Ustianowski, A. (2021). Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med., 384, 693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"ref_65","unstructured":"(2022, February 19). Therapeutic Management of Hospitalized Adults with COVID-19, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults--therapeutic-management\/."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Fahn\u00f8e, U., Ronit, A., Berg, R.M.G., J\u00f8rgensen, S.E., Mogensen, T.H., Underwood, A.P., Scheel, T.K.H., Bukh, J., and Plovsing, R.R. (2022). A distinct dexamethasone- dependent gene expression profile in the lungs of COVID-19 patients. J. Infect. Dis., jiac218.","DOI":"10.1101\/2022.01.12.22269048"},{"key":"ref_67","unstructured":"(2022, February 19). Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19."},{"key":"ref_68","unstructured":"(2022, February 19). Paxlovid for Treatment of COVID-19. Available online: https:\/\/secure.medicalletter.org\/w1642a."},{"key":"ref_69","unstructured":"FDA (2022, February 19). Fact Sheet for Health Care Providers: Emergency Use Authorization for Molnupiravir, Available online: https:\/\/www.fda.gov\/media\/155054\/download?utm_medium=email&utm_source=govdelivery."},{"key":"ref_70","unstructured":"(2022, February 19). FDA Approves First Treatment for COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","first-page":"100998","article-title":"Omicron SARS-CoV-2 variant: What we know and what we don\u2019t","volume":"4","author":"Visseaux","year":"2022","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"ref_74","unstructured":"(2022, February 18). Dual mAb Therapy Reduces Viral Load in Patients with Mild to Moderate COVID-19. Available online: https:\/\/hospitalpharmacyeurope.com\/covid-19\/dual-mab-therapy-reduces-viral-load-in-patients-with-mild-to-moderate-covid-19\/."},{"key":"ref_75","unstructured":"NIH (2022, February 18). COVID-19 Treatment Guidelines; Anti-SARS-CoV-2 Monoclonal Antibodies, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/anti-sars-cov-2-antibody-products\/anti-sars-cov-2-monoclonal-antibodies\/."},{"key":"ref_76","unstructured":"(2022, February 19). Bebtelovimab (LY-CoV1404) Monoclonal Antibody. Available online: https:\/\/www.precisionvaccinations.com\/vaccines\/bebtelovimab-ly-cov1404-monoclonal-antibody."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s40121-021-00525-4","article-title":"Efficacy of Bamlanivimab\/Etesevimab and Casirivimab\/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern","volume":"10","author":"Falcone","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","unstructured":"Aleem, A., Akbar Samad, A.B., and Slenker, A.K. (2022, May 20). Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570580."},{"key":"ref_80","unstructured":"(2022, February 19). Bamlanivimab and Etesevimab Authorized States, Territories, and U.S. Jurisdictions, Available online: https:\/\/www.fda.gov\/media\/151719\/download."},{"key":"ref_81","unstructured":"(2022, February 19). Medlineplus: Bamlanivimab and Etesevimab Injection, Available online: https:\/\/medlineplus.gov\/druginfo\/meds\/a621008.html."},{"key":"ref_82","unstructured":"(2022, February 19). Therapeutic Antibodies for COVID-19. Available online: https:\/\/evidentic.com\/therapeutic-antibodies-for-covid-19\/."},{"key":"ref_83","unstructured":"(2022, February 19). UPDATE\u2014Allocation of Bamlanivimab\/Etesevimab and REGEN-COV Therapeutics Paused, Available online: https:\/\/www.phe.gov\/emergency\/events\/COVID19\/investigation-MCM\/Bamlanivimab-etesevimab\/Pages\/important-update-24Jan2022.aspx."},{"key":"ref_84","unstructured":"Food and Drug Administration (2022, February 19). Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Sotrovimab, Available online: https:\/\/www.fda.gov\/media\/149534\/download."},{"key":"ref_85","unstructured":"(2022, February 19). Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. Available online: https:\/\/secure.medicalletter.org\/w1641a."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1468\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:23:21Z","timestamp":1760142201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":85,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["vaccines10091468"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10091468","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]}}}